Azaserine, DON, and azotomycin: three diazo analogs of L-glutamine with clinical antitumor activity.
A review of the clinical data on azaserine, DON, and azotomycin reveals that these agents have limited but definite antitumor activity. All three drugs are analogs of L-glutamine and contain a diazo group. They have been studied as single agents in a wide variety of human malignancies and have also been included in trials using combination chemotherapy. Most of these studies were performed early in the history of clinical trials and, therefore, the method of reporting results and the evaluation criteria were quite different from those in use today. A renewed interest in these agents has been triggered by the remarkable activity of DON and azotomycin against human tumor lines implanted into nude mice. On the basis of this activity and the clinical data we have compiled, we feel that new clinical trials with these agents are warranted.
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage; D001377:Azaserine / Q000627:therapeutic use*; D001391:Azo Compounds / Q000627:therapeutic use*; D003110:Colonic Neoplasms / Q000188:drug therapy; D003980:Diazooxonorleucine / Q000627:therapeutic use*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D009369:Neoplasms / Q000188:drug therapy*; D009374:Neoplasms, Experimental / Q000188:drug therapy; D014183:Transplantation, Heterologous
D000970:Antineoplastic Agents; D001391:Azo Compounds; D003980:Diazooxonorleucine; D001377:Azaserine